Ensysce Biosciences Inc, a development stage company for abuse deterrent opioid and ADHD drug prodrugs will present at the 9th Annual Biotech Showcase 2017, Hilton San Francisco Union Square.
On January 11, 2017, Dr. Lynn Kirkpatrick, CEO will present an overview of the company’s BIO-MD prodrug abuse deterrent and MPAR overdose resistant pain platforms along with the first phase 1 pharmacokinetic data for its oxycodone prodrug, PF614, from an ongoing phase 1 trial.
Ensysce Biosciences, San Diego, CA, is an integrated drug delivery company for both small and large molecules, using prodrug technology and single walled carbon nanotubes respectively. The BIO-MD prodrug abuse deterrent and MPAR overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route, the fastest growing drug problem in the US that leads to billions in healthcare costs annually. The Ensysce product pipeline includes immediate-release (IR) or extended-release (ER) prodrugs with timed activation of opioids and stimulants that present challenges for duration of action and abuse-deterrence.
Additionally, Ensysce’s combination MPAR products provide overdose protection to these products. The BIO-MD and MPAR technology have been demonstrated with PF329, an extended-release hydromorphone prodrug in a phase 1 clinical study. The current phase 1 clinical trial for the BIO-MD abuse deterrent oxycodone prodrug, PF614 initiated in November 2016 and is continuing to dose escalate through early 2017.